BillionToOne wins EUA for RNA extraction-free COVID-19 test

By staff writers

September 9, 2020 -- Diagnostics firm BillionToOne has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its qSanger-COVID-19 assay, a SARS-CoV-2 test that obviates the need for RNA extraction.

In contrast to other molecular assays that utilize RNA extraction and quantitative reverse transcription polymerase chain reaction (RT-PCR) techniques, qSanger-COVID-19 assay uses a different set of instruments and chemicals from existing tests, according to the company. It can be easily adopted with minimum training at any laboratories with Sanger sequencers, BillionToOne said.

BillionToOne's qSanger-COVID-19 assay doesn't require RNA extraction and is used with Sanger sequencers. Image courtesy of BillionToOne.

The company said that it utilized Swift Biosciences' custom manufacturing and distribution capabilities to complete development of the tests and initiate international distribution in May. Brazilian medical diagnostics laboratory DASA has adopted the qSanger-COVID-19 assay, BillionToOne said. In addition, BillionToOne and Swift said they are working together with multiple clinical laboratories in the U.S. and around the world to help them adopt the testing protocol.

FDA grants DetectaChem EUA for mobile COVID-19 test
The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to DetectaChem for its mobile COVID-19 test kit.
Experts draw lessons from FDA's hydroxychloroquine EUA controversy
Public health and regulatory experts advocated for changes to the U.S. Food and Drug Administration (FDA) emergency use authorization (EUA) process in...
Maxim Biomedical on track to make 3M COVID-19 tests
Maxim Biomedical plans to produce and market as many as 3 million Maxim SARS-CoV-2 rapid antigen diagnostic tests by the end of the year.
Detecting SARS-CoV-2 in blood may be early indicator of severe disease
A blood test that measures SARS-CoV-2 RNA when patients are admitted to the hospital with COVID-19 symptoms can be a powerful diagnostic tool to predict...
NIH to spend $129M to scale up COVID-19 testing
The U.S. National Institutes of Health (NIH) plans to spend about $129 million to scale up COVID-19 testing capacity and provide manufacturing support....

Copyright © 2020

Last Updated ls 9/21/2020 8:19:26 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current